TA 6666
Alternative Names: TA-6666Latest Information Update: 25 May 2010
Price :
$50 *
At a glance
- Originator Tanabe Seiyaku
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 12 May 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO)
- 12 May 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation